Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
6/9/2026, 12:00:00 AM
Merck and partner Gilead Sciences announced they are halting the Phase 3 EVOKE-03 trial on 2026-06-09; importance is estimated at Medium due to high expectations for Keytruda combination therapies, expected.
Korean Translation
2026-06-09 3상 EVOKE-03 임상 중단 발표. 키트루다 병용 요법에 대한 높은 기대치를 고려할 때 약 5% 이상의 부정적 영향이 예상되어 Medium으로 분류함, 예상됨.
Related Recent Events
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026, with medium importance estimated due to typical market volatility following results, scheduled.
8/18/2026, 12:00:00 AM
Exxon Mobil Corp (XOM) · Earnings Release
Q2 2026 earnings release scheduled.
7/31/2026, 12:00:00 AM
The Cigna Group (CI) · Earnings Release
The Cigna Group is scheduled to release its Q2 2026 financial results before the market opens on July 30, 2026, scheduled. Expected price impact of ~5% based on historical earnings volatility.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
7/30/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Earnings Release
Q4 and full-year fiscal 2026 earnings release on 2026-07-29; low impact due to routine scheduling announcement scheduled.
7/29/2026, 12:00:00 AM
Illinois Tool Works Inc. (ITW) · Earnings Release
Illinois Tool Works is scheduled to release its Q2 2026 earnings on July 29, 2026, with analysts forecasting EPS of approximately $2.79. This routine announcement is estimated to have a Low importance (>=1% impact), scheduled.
7/29/2026, 12:00:00 AM